Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1974 1
1978 2
1979 2
1980 2
1983 1
1984 2
1986 2
1987 2
1988 2
1989 4
1990 3
1993 1
1994 1
1997 1
2001 2
2006 1
2009 1
2015 1
2016 3
2017 1
2018 1
2019 2
2020 12
2021 10
2022 9
2023 3
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Communication during crisis.
Eldridge CC, Hampton D, Marfell J. Eldridge CC, et al. Nurs Manage. 2020 Aug;51(8):50-53. doi: 10.1097/01.NUMA.0000688976.29383.dc. Nurs Manage. 2020. PMID: 32675739 Review.
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Schoser B, et al. Lancet Neurol. 2021 Dec;20(12):1027-1037. doi: 10.1016/S1474-4422(21)00331-8. Lancet Neurol. 2021. PMID: 34800400 Clinical Trial.
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, Byrne BJ, Claeys KG, Díaz-Manera J, Laforêt P, Roberts M, Toscano A, van der Ploeg AT, Castelli J, Goldman M, Holdbrook F, Sitaraman Das S, Wasfi Y, Mozaffar T; ATB200-07 Study Group. Schoser B, et al. J Neurol. 2024 May;271(5):2810-2823. doi: 10.1007/s00415-024-12236-0. Epub 2024 Feb 28. J Neurol. 2024. PMID: 38418563 Free PMC article. Clinical Trial.
Emerging good practices for Translatability Assessment (TA) of Patient-Reported Outcome (PRO) measures.
Acquadro C, Patrick DL, Eremenco S, Martin ML, Kuliś D, Correia H, Conway K; International Society for Quality of Life Research (ISOQOL) Translation and Cultural Adaptation Special Interest Group (TCA-SIG). Acquadro C, et al. J Patient Rep Outcomes. 2017;2(1):8. doi: 10.1186/s41687-018-0035-8. Epub 2018 Feb 21. J Patient Rep Outcomes. 2017. PMID: 29757337 Free PMC article. Review.
Postfolate spina bifida lesion level change.
Eldridge C, Bandlamuri S, Andrews JG, Galindo MK, Contreras D, Flood TJ, Rice S. Eldridge C, et al. Birth Defects Res. 2018 Jul 3;110(11):949-955. doi: 10.1002/bdr2.1221. Epub 2018 Mar 25. Birth Defects Res. 2018. PMID: 29575817
The Impact of Smoking Cessation Therapy on Lumbar Fusion Outcomes.
Khalid SI, Thomson KB, Chilakapati S, Singh R, Eldridge C, Mehta AI, Adogwa O. Khalid SI, et al. Among authors: eldridge c. World Neurosurg. 2022 Aug;164:e119-e126. doi: 10.1016/j.wneu.2022.04.031. Epub 2022 Apr 16. World Neurosurg. 2022. PMID: 35439621
67 results